Business Standard

Monday, December 23, 2024 | 10:37 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zydus receives USFDA final approval for Vigabatrin Tablets

Image

Capital Market

Used to treat epilepsy in babies

Zydus has received final approval from the USFDA to market Vigabatrin Tablets in the strength of 500 mg (US RLD: Sabril Tablets).

Vigabatrin is used to treat babies, one month to 2 years old with infantile spasms. It is also used in combination with other medications to treat seizure disorders (epilepsy). Vigabatrin decreases the number of seizures in adults and children who have not been able to control their seizures with other treatment. Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

 

The group now has 326 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 20 2022 | 10:53 AM IST

Explore News